The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
 
Bianca van Veggel
No Relationships to Disclose
 
Anthonie J. van der Wekken
Honoraria - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Marthe Paats
No Relationships to Disclose
 
Sayed MS Hashemi
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Loxo; MSD; Novartis; Roche; Takeda; Xcovery
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BMSi (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Xcovery (Inst)
 
Lizza Hendriks
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Roche/Genentech; Roche/Genentech (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
Speakers' Bureau - Medtalks; MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - AstraZeneca; AstraZeneca (Inst); BluPrint Oncology (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Karolina Sikorska
No Relationships to Disclose
 
Daan van den Broek
Consulting or Advisory Role - Roche Molecular Diagnostics (Inst)
 
Kim Monkhorst
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Diaceutics (Inst); Lilly (Inst); MSD (Inst); Roche (Inst)
Speakers' Bureau - AstraZeneca (Inst); Benecke (Inst); MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Delfi Diagnostics (Inst); Personal Genome Diagnostics (Inst)
Travel, Accommodations, Expenses - Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Egbert F. Smit
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Joop De Langen
Consulting or Advisory Role - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merus (Inst); MSD Oncology (Inst); Roche (Inst)